u/mrmrmrj ·
Reddit — r/ValueInvesting
· May 05, 2026 at 14:57
· ⬆ 19 pts
· 💬 34 comments
| View on Reddit ↗
AI Summary
Summary
Post argues healthcare sector’s S&P market cap share has collapsed to 1994-like lows despite rising GDP spending (10%→21% since 1994).
Author draws a historical parallel to the 1994 Clinton price‑control scare that was thwarted, leading to a pharma surge; sees similar opportunity today.
Quality assessment: Well-researched DD with historical data and sector‑level analysis, though individual stock picks are subjective.
Score19
Comments34
Upvote %95%
▶ Full Post Text
I wish I could show you the chart I am looking at but I will describe it.
Healthcare spending as a share of US GDP has been in a long-term uptrend since 1994. It wobbles a little bit as other sectors surge in the short term (like the dot com boom) but it relentlessly marches up and to the right as our population ages, from 10% of GDP to 21% today.
On the flip side, the market cap of the S&P Healthcare sector has utterly collapsed since 2020, from 16% to 10%, almost eclipsing the 1994 low late in early 2025. Over time, the mkt cap share has tracked the trendline of GDP share but with more volatility. In general, when the GDP share has inflected up, the mkt cap share has inflected up more and vice versa.
What was happening in 1994? The Clinton administration was publicly positioning for massive price controls on the pharmaceutical industry. This policy was thwarted, resulting in a surge of the pharma stocks from 1994 to 1996.
So here we are again with maximum relative pessimism about the US healthcare sector in the stock market while healthcare spending relentlessly climbs.
This has happened DESPITE LLY close to all time highs and being 14% of the S&P healthcare sector. JNJ is #2 at 7% after a MONSTER move. The top two stocks have done really, really well but the sector's total market share has collapsed.
Therein lies an opportunity. XLV is the ETF for the sector. My personal fav is MDT which is #16 in the holdings ranking and just rolled over like a dying bird. TMO is #7 and has moved sideways for 5 years. Those are two places to start.
TMO (#7 in XLV) “has moved sideways for 5 years,” underperforming despite steady earnings growth from life sciences tools. A multi‑year consolidation often precedes a breakout; sector re‑rating would finally reward TMO’s fundamental stability. Thermo Fisher offers exposure to healthcare innovation (lab equipment, diagnostics) at a compressed valuation relative to its historical multiples. Slowing biopharma capex, post‑pandemic demand normalization, or geopolitical disruption to supply chains.
MDT (#16 in XLV holdings) “just rolled over like a dying bird,” implying deep undervaluation within a cheap sector. Medtronic is a diversified med‑tech bellwether; if the sector mean‑reverts, laggards like MDT often see outsized gains. A contrarian pick on a beaten‑down quality name with a strong historical franchise in medical devices. Regulatory headwinds (device taxes, FDA delays), competitive pressure from newer players, or continued margin compression.
Healthcare spending as % of GDP is in a long‑term uptrend (10%→21%), but XLV’s S&P weight dropped from 16% to 10%, near 1994 lows. When the GDP share inflects up, the market‑cap share has historically surged. Maximum pessimism now resembles the 1994‑1996 pharma rally catalyst. Buying the sector ETF XLV bets on mean reversion as aging demographics and policy fears fade, capturing the entire cheap sector. Renewed price‑control legislation (e.g., IRA expansion), recession cutting healthcare spending, or a tech/AI bubble stealing capital.
This Reddit post, published May 05, 2026,
features u/mrmrmrj
discussing TMO, MDT, XLV.
3 trade ideas extracted by AI with direction and confidence scoring.